Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer
- 1 June 2018
- journal article
- editorial
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 13 (6), 741-744
- https://doi.org/10.1016/j.jtho.2018.04.008
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung CancerJournal of Thoracic Oncology, 2018
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenThe New England Journal of Medicine, 2018
- Cancer immunotherapy using checkpoint blockadeScience, 2018
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 2016
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016
- PS01.63: Clinical Characteristics of Acquired Resistance with Anti-PD-1/PD-L1 in Non–Small Cell Lung Cancer (NSCLC)Journal of Thoracic Oncology, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015